Medical device manufacturing operates under structural constraints that differ from both pharma and general manufacturing. Long product lifecycles (5-15 years versus 2-5 years for many industries) mean demand patterns evolve through clear lifecycle phases � launch, growth, maturity, decline � with different forecasting needs in each. Regulatory environments (FDA QSR, EU MDR, ISO 13485) require traceability, change control, and validated environments for systems affecting product release. Customer-specific configurations are common, particularly in implants and capital equipment. Service parts demand for installed bases adds long-tail SKU complexity that pure-manufacturing platforms often handle poorly.
The platforms that fit medical device demand planning are a subset of the broader category � specifically those with audit trail depth, lifecycle-aware forecasting, configuration management, and service parts capability. This page covers that subset.
Horizon fits medical device manufacturers $100M-$3B revenue, typically Class I and Class II device makers, specialty device manufacturers, contract manufacturing organizations (CMOs) supplying medical device customers, and surgical instrument or implant makers in the mid-market range. The ensemble forecasting approach handles the lifecycle heterogeneity that's characteristic of medical device portfolios � products in different lifecycle phases need different forecasting methods, and per-SKU automatic model selection picks the right one.
What works well technically: the audit trail captures every forecast overlay, approval, and override with timestamps and user identification � meets the documentation expectations of FDA QSR and ISO 13485 quality reviews. Service parts capability handles long-tail installed-base demand with intermittent patterns. Configuration management supports product variations without forcing every SKU to be a separate planning unit.
Where Horizon doesn't fit: top-20 medtech enterprises with Class III device portfolios and validation cycles extending to 12-24 months regardless of platform technical capability � those operations typically fit SAP IBP, Kinaxis, or OMP better. Operations with primarily implant or capital equipment business where individual customer order management dominates over forecasting may need ETO-focused platforms. We'll be specific about fit in early conversations.
Like pharma, medical device demand planning evaluation puts algorithm capability as a secondary factor. The bigger factors are: validated environment capability (the platform supports qualification appropriate for FDA QSR or EU MDR), audit trail depth (every forecast overlay has who/when/why documentation), lifecycle-aware methods (different forecasting approaches for launch vs mature vs end-of-life products), service parts handling (long-tail SKU demand for installed bases), and reference customers in medical devices.
The platforms with established medical device capability are typically mature in the industry. Newer entrants can deploy in medical devices but lack the reference base and validation approach that medical device quality teams expect. The list below distinguishes by what platforms have demonstrated capability versus what they market.
Built for: Large medical device manufacturers running SAP S/4HANA.
Strengths: Mature medical device reference base. Native SAP integration including SAP QM for quality. Audit trail aligned with regulatory expectations.
Limitations: Implementation 12-24 months. TCO $1M+ annually.
Built for: Large medical device manufacturers wanting concurrent planning. 2026 Gartner MQ Leader.
Strengths: Established medical device reference base. Concurrent planning supports rapid scenario evaluation during supply disruptions.
Limitations: Enterprise cost and complexity.
Built for: Large medical device enterprises wanting AI-driven planning.
Strengths: Knowledge graph handles complex product configurations and customer-specific demand. Strong external data integration.
Built for: Process-heavy medical device operations including biotech and consumables manufacturing.
Strengths: Strong process-industry capability. Established in medical and biotech.
Built for: Medical device manufacturers $100M-$3B revenue. Particularly Class I and Class II device makers, specialty manufacturers, and contract manufacturers.
Strengths: Ensemble forecasting handles lifecycle-phase heterogeneity � different methods for launch products, mature products, and end-of-life products within the same portfolio. Audit trail captures every overlay with who/when/why for quality reviews. Service parts capability for long-tail installed-base demand. Configuration-driven deployment in 6-10 weeks per module.
Limitations: Not built for Class III complex regulatory burden at top-20 medtech scale. Validation approach supports mid-market quality reviews but doesn't replace top-20 medtech validation programs.
Built for: Mid-market medical device manufacturers.
Strengths: AI through Logility Expert Advisor. Mature reference base across regulated industries.
Built for: Mid-market medical and life sciences manufacturers.
Strengths: Atlas Planning platform with demand planning depth.
Probabilistic methods help with service parts (intermittent demand) and long-tail installed-base SKUs.
Probabilistic AI-driven planning. Smaller medical device reference base than established platforms.
Three factors drive the shortlist. First, regulatory burden: Class III devices with extensive FDA submission requirements typically fit enterprise platforms (SAP IBP, Kinaxis, OMP) with established validation; Class I and II often fit mid-market integrated platforms with documented validation support (Horizon, Logility, John Galt). Second, product portfolio complexity: high configuration variability favors platforms with strong product structure handling (SAP IBP, Kinaxis, o9, Horizon); simpler portfolios have more options. Third, installed base service parts: significant aftermarket business favors platforms with strong service parts capability (Horizon, ToolsGroup, Logility).
